Profile picture

Doctor Corina Becker

Bayer AG, Wuppertal (Germany)
Follow
Logo ESC

Contributor content

Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
Presentation
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
Read more
Pharmacodynamic interaction study of a long-acting nitrate co-administered with vericiguat in patients with stable coronary artery disease
Presentation
Pharmacodynamic interaction study of a long-acting nitrate co-administered with vericiguat in patients with stable coronary artery disease
Read more
Pharmacodynamic and pharmacokinetic interaction profile of vericiguat
Presentation
Pharmacodynamic and pharmacokinetic interaction profile of vericiguat
Read more
Safety, pharmacodynamic and pharmacokinetic characterisation of vericiguat: key results from six phase I studies in healthy subjects
Presentation
Safety, pharmacodynamic and pharmacokinetic characterisation of vericiguat: key results from six phase I studies in healthy subjects
Read more

ESC 365 is supported by

novartis Explore sponsored resources